PET imaging with β-amyloid ligands is emerging as a molecular imaging technique targeting white matter integrity and demyelination. β-amyloid PET ligands such as 11C-Pittsburgh compound B (11C-PiB) have been considered for quantitative measurement of myelin content changes in multiple sclerosis, but 11C-PiB is not commercially available given its short half-life. A 18F PET ligand such as flutemetamol with a longer half-life may be an alternative, but its ability to differentiate white matter hyperintensities (WMH) from normal-appearing white matter (NAWM) and its relationship with age remains to be investigated. Methods: Cognitively unimpaired (CU) older and younger adults (n = 61) were recruited from the community responding to a study advertisement for β-amyloid PET. Participants prospectively underwent MRI, 11C-PiB, and 18F-flutemetamol PET scans. MRI fluid-attenuated inversion recovery images were segmented into WMH and NAWM and registered to the T1-weighted MRI. 11C-PiB and 18F-flutemetamol PET images were also registered to the T1-weighted MRI. 11C-PiB and 18F-flutemetamol SUV ratios (SUVrs) from the WMH and NAWM were calculated using cerebellar crus uptake as a reference for both 11C-PiB and 18F-flutemetamol. Results: The median age was 38 y (range, 30-48 y) in younger adults and 67 y (range, 61-83 y) in older adults. WMH and NAWM SUVrs were higher with 18F-flutemetamol than with 11C-PiB in both older (P < 0.001) and younger (P < 0.001) CU adults. 11C-PiB and 18F-flutemetamol SUVrs were higher in older than in younger CU adults in both WMH (P < 0.001) and NAWM (P < 0.001). 11C-PiB and 18F-flutemetamol SUVrs were higher in NAWM than WMH in both older (P < 0.001) and younger (P < 0.001) CU adults. There was no apparent difference between 11C-PiB and 18F-flutemetamol SUVrs in differentiating WMH from NAWM in older and in younger adults. Conclusion: 11C-PiB and 18F-flutemetamol show a similar topographic pattern of uptake in white matter with a similar association with age in WMH and NAWM. 11C-PiB and 18F-flutemetamol can also effectively distinguish between WMH and NAWM. However, given its longer half-life, commercial availability, and higher binding potential, 18F-flutemetamol can be an alternative to 11C-PiB in molecular imaging studies specifically targeting multiple sclerosis to evaluate white matter integrity.
PET imaging with β-amyloid ligands is emerging as a molecular imaging technique targeting white matter integrity and demyelination. β-amyloid PET ligands such as 11C-Pittsburgh compound B (11C-PiB) have been considered for quantitative measurement of myelin content changes in multiple sclerosis, but 11C-PiB is not commercially available given its short half-life. A 18F PET ligand such as flutemetamol with a longer half-life may be an alternative, but its ability to differentiate white matter hyperintensities (WMH) from normal-appearing white matter (NAWM) and its relationship with age remains to be investigated. Methods: Cognitively unimpaired (CU) older and younger adults (n = 61) were recruited from the community responding to a study advertisement for β-amyloid PET. Participants prospectively underwent MRI, 11C-PiB, and 18F-flutemetamol PET scans. MRI fluid-attenuated inversion recovery images were segmented into WMH and NAWM and registered to the T1-weighted MRI. 11C-PiB and 18F-flutemetamol PET images were also registered to the T1-weighted MRI. 11C-PiB and 18F-flutemetamol SUV ratios (SUVrs) from the WMH and NAWM were calculated using cerebellar crus uptake as a reference for both 11C-PiB and 18F-flutemetamol. Results: The median age was 38 y (range, 30-48 y) in younger adults and 67 y (range, 61-83 y) in older adults. WMH and NAWM SUVrs were higher with 18F-flutemetamol than with 11C-PiB in both older (P < 0.001) and younger (P < 0.001) CU adults. 11C-PiB and 18F-flutemetamol SUVrs were higher in older than in younger CU adults in both WMH (P < 0.001) and NAWM (P < 0.001). 11C-PiB and 18F-flutemetamol SUVrs were higher in NAWM than WMH in both older (P < 0.001) and younger (P < 0.001) CU adults. There was no apparent difference between 11C-PiB and 18F-flutemetamol SUVrs in differentiating WMH from NAWM in older and in younger adults. Conclusion: 11C-PiB and 18F-flutemetamol show a similar topographic pattern of uptake in white matter with a similar association with age in WMH and NAWM. 11C-PiB and 18F-flutemetamol can also effectively distinguish between WMH and NAWM. However, given its longer half-life, commercial availability, and higher binding potential, 18F-flutemetamol can be an alternative to 11C-PiB in molecular imaging studies specifically targeting multiple sclerosis to evaluate white matter integrity.
Authors: Chunying Wu; Changning Wang; Daniela C Popescu; Wenxia Zhu; Eduardo A Somoza; Junqing Zhu; Allison G Condie; Christopher A Flask; Robert H Miller; Wendy Macklin; Yanming Wang Journal: Bioorg Med Chem Date: 2010-11-09 Impact factor: 3.641
Authors: Victor L Villemagne; Rachel S Mulligan; Svetlana Pejoska; Kevin Ong; Gareth Jones; Graeme O'Keefe; J Gordon Chan; Kenneth Young; Henri Tochon-Danguy; Colin L Masters; Christopher C Rowe Journal: Eur J Nucl Med Mol Imaging Date: 2012-03-08 Impact factor: 9.236
Authors: Val J Lowe; Emily S Lundt; Matthew L Senjem; Christopher G Schwarz; Hoon-Ki Min; Scott A Przybelski; Kejal Kantarci; David Knopman; Ronald C Petersen; Clifford R Jack Journal: J Nucl Med Date: 2018-04-19 Impact factor: 10.057
Authors: Chunying Wu; Junqing Zhu; Jonathan Baeslack; Anita Zaremba; Jordan Hecker; Janet Kraso; Paul M Matthews; Robert H Miller; Yanming Wang Journal: Ann Neurol Date: 2013-09-23 Impact factor: 10.422
Authors: Daniele de Paula Faria; Sjef Copray; Jurgen W A Sijbesma; Antoon T M Willemsen; Carlos A Buchpiguel; Rudi A J O Dierckx; Erik F J de Vries Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-06 Impact factor: 9.236
Authors: James P Fisher; Doreen Hartwich; Thomas Seifert; Niels D Olesen; Clare L McNulty; Henning B Nielsen; Johannes J van Lieshout; Niels H Secher Journal: J Physiol Date: 2012-12-10 Impact factor: 5.182
Authors: Burcu Zeydan; Christopher G Schwarz; Val J Lowe; Robert I Reid; Scott A Przybelski; Timothy G Lesnick; Walter K Kremers; Matthew L Senjem; Jeffrey L Gunter; Hoon-Ki Min; Prashanthi Vemuri; David S Knopman; Ronald C Petersen; Clifford R Jack; Orhun H Kantarci; Kejal Kantarci Journal: Ann Clin Transl Neurol Date: 2019-03-03 Impact factor: 4.511
Authors: James M Mountz; Charles M Laymon; Ann D Cohen; Zheng Zhang; Julie C Price; Sanaa Boudhar; Eric McDade; Howard J Aizenstein; William E Klunk; Chester A Mathis Journal: Neuroimage Clin Date: 2015-10-14 Impact factor: 4.881